HTA Evolution & Pricing Realities

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, health economist, and it's great to have you with us today.

SaraAnd I'm Sara, market access strategy. Always good to be here — and I'll say, today's topics feel particularly timely given the shifting regulatory winds.

MarcusExactly. We're looking at the EU HTA Regulation's operational friction points — why implementation delays matter for evidence strategies. Then CMS Part D redesign's real-world implementation hurdles — budget impact implications are significant. And the evolving role of RWE in supporting FDA accelerated approvals — evidence standards are shifting.

SaraThat second one resonates deeply — the Part D redesign's operational disconnect between policy intent and pharmacy-level execution could create massive budget volatility for payers.

MarcusAgreed. Let's get into it.

MarcusStarting with the EU HTA Regulation. The first batch of joint clinical assessments for oncology drugs is facing significant procedural delays. Not just timeline slips, but fundamental bottlenecks in harmonizing methodologies across member states.

SaraThat's one read — but I'd frame it slightly differently. The real friction is in the parallel scientific advice process. Member states are still operating in silos despite the JCA framework, creating contradictory evidence requirements that fragment developer resources.

MarcusWhat strikes me about that is the resource drain. Companies are now duplicating submissions for essentially identical dossiers across national agencies. That's a direct hit on HEOR efficiency budgets.

SaraAnd the budget impact cascades down — when companies spend more on fragmented evidence generation, that's less investment in core value demonstration. The part that gives me pause is how this delays patient access for genuinely innovative therapies.

MarcusThat's fair, though I think payers would see it differently. They're frustrated by the inconsistency in value assessments across borders. One country's cost-effectiveness threshold is another's budget crisis.

SaraExactly. And what's interesting is how this fragmentation undermines the entire premise of the HTA Regulation. The promise was efficiency, but we're seeing administrative overhead increase instead.

MarcusThe historical precedent here is telling. Look at the early days of NICE technology appraisals — similar teething problems. The question is whether the EU can course-correct faster than the UK did.

SaraFaster course-correction requires genuine political will, not just procedural tweaks. And that's where I remain skeptical.

SaraShifting to CMS Part D redesign. The implementation is revealing critical gaps between policy design and pharmacy operations. The negotiation windows and inflation rebates are creating operational chaos at the dispensing level.

MarcusI wonder if that's the full picture though. The real issue is the mismatch between Part D's risk corridor structure and actual drug utilization patterns. Manufacturers are now forced to negotiate based on utilization projections that don't reflect real-world prescribing.

SaraThat connects to something I keep coming back to — the budget impact uncertainty. Payers can't model costs when manufacturers are simultaneously adjusting prices mid-year based on IRA negotiations.

MarcusWhat's striking here is the precedent it sets for future pricing models. If CMS allows this level of operational flexibility, it erodes the predictability that both payers and manufacturers need for sustainable access.

SaraThe operational hurdles extend to patient access too. Pharmacists report confusion over coverage determination timelines, leading to prior authorization delays for complex therapies.

MarcusThat's fair, though I think payers would see it differently. Their concern is the cost-shifting — when manufacturers lower list prices but increase rebates, the net impact on formulary placement remains opaque.

SaraAnd the transparency gap is growing. We're seeing more confidential pricing agreements that make it impossible to assess true system value.

MarcusThe methodological observation here is critical. Without standardized reporting of net prices and rebates, any cost-effectiveness analysis becomes fundamentally flawed.

SaraExactly. And that's why this implementation matters globally — it's setting precedents for how value-based pricing operates in mature markets.

MarcusNow to RWE in accelerated approvals. The FDA's recent guidance emphasizes the need for post-marketing RWE to confirm clinical benefit, but the methodological standards remain ambiguous.

SaraThat's one read — I'd push back slightly. The real challenge is in designing RWE studies that can withstand HTA scrutiny. Payers need more than just real-world data; they need causal inference methodologies that match RCT rigor.

MarcusWhat strikes me about that is the temporal disconnect. FDA accelerated approvals often come before robust RWE infrastructure exists, creating evidence gaps that undermine long-term value demonstration.

SaraAnd the budget impact question there is one the field hasn't fully worked out yet. How do you price a therapy based on accelerated approval when the confirmatory RWE might take years to generate?

MarcusThe historical precedent is the oncology space. Many drugs with accelerated approvals still lack confirmatory data years later, leaving payers in perpetual uncertainty.

SaraThis is one of those stories where the regulatory tail wags the access dog. The FDA's focus on speed creates downstream HEOR challenges that manufacturers haven't adequately prepared for.

MarcusThat's fair, though I think payers would see it differently. They're increasingly demanding RWE plans as a condition of coverage, not just post-marketing commitments.

SaraAnd what's interesting is how this shifts the evidence generation timeline. Companies now need to think about RWE strategies before Phase III enrollment, not after approval.

MarcusThe methodological observation here is crucial. Without standardized RWE endpoints that align with HTA requirements, we'll continue to see value assessments based on incomplete evidence.

SaraExactly. And that's why this topic matters globally — it's redefining how we define clinical benefit across regulatory and HTA boundaries.

SaraFinally, gene therapy cost-effectiveness thresholds. High-income markets are struggling to justify ultra-high-price therapies, particularly when benefits are incremental or uncertain.

MarcusI'd frame it slightly differently. The real issue is the temporal disconnect between one-time costs and long-term value. Traditional cost-effectiveness models can't capture the generational impact of curative therapies.

SaraWhat gives me pause is the precedent being set. When HTA bodies like NICE reject gene therapies based on standard thresholds, it signals that the current framework may be fundamentally mismatched to these technologies.

MarcusThat connects to something I keep coming back to — the opportunity cost argument. When a single gene therapy consumes 10% of a rare disease budget, what's the impact on other innovative therapies?

SaraAnd the budget impact question is particularly acute in smaller markets. A single ultra-orphan drug can dominate an entire country's rare disease budget.

MarcusThe historical precedent here is CAR-T cell therapies. We saw similar threshold debates five years ago, but the evidence generation has improved since then.

SaraThis is one of those stories where the evidence evolves faster than the methodologies. We need new value assessment frameworks that can capture one-time cure models.

MarcusThat's fair, though I think payers would see it differently. They're demanding more risk-sharing agreements to mitigate budget impact, which manufacturers are increasingly reluctant to offer.

SaraAnd what's interesting is how this creates a two-tiered access system. Countries with deep pockets get gene therapies; others don't, regardless of clinical need.

MarcusThe methodological observation here is critical. Without generational cost-offset modeling and multi-criteria decision analysis, we'll continue to struggle with these therapies.

SaraExactly. And that's why this topic matters globally — it's forcing a fundamental rethinking of how we value transformative medicines.

SaraA lot to think about today. I'll be watching how EU member states navigate the HTA Regulation's operational friction points — particularly whether we see genuine harmonization emerge.

MarcusSame — and for me the thread running through today is the tension between regulatory speed and evidence robustness. Whether it's accelerated approvals or gene therapies, the system is struggling to match pace with innovation.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.